Zygote Intrafallopian Transfer (ZIFT) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Zygote Intrafallopian Transfer (ZIFT) is an assisted reproductive technique in which oocytes are fertilised in vitro and the resulting pronucleate zygotes — typically at the two-pronuclei (2PN) stage, approximately 16–18 hours after fertilisation — are transferred laparoscopically into the fallopian tube. The rationale is that the fallopian tube provides a physiologically superior environment for early embryo development compared with the culture medium of an in vitro laboratory, with the expectation that the embryo will travel naturally to the uterus over the subsequent 3–5 days.

ZIFT was developed in the late 1980s as a hybrid between conventional IVF and Gamete Intrafallopian Transfer (GIFT). It differs from GIFT in a critical way: GIFT transfers unfertilised eggs and sperm directly into the tube, so fertilisation itself occurs in the tube; ZIFT transfers an already-fertilised zygote (confirmed fertilisation), making it possible to verify that fertilisation has occurred before proceeding to the invasive laparoscopic transfer step.

Compared with standard IVF, ZIFT adds a laparoscopic surgical step under general anaesthesia for the embryo transfer. In conventional IVF, transfer is performed transcervically under ultrasound guidance as a simple outpatient procedure without anaesthesia, using embryos cultured to cleavage stage (day 2–3) or blastocyst stage (day 5–6). The additional invasiveness of ZIFT — and the widespread adoption of optimised IVF culture media and blastocyst transfer — led to a progressive decline in ZIFT utilisation from the mid-1990s. It now represents a small fraction of assisted reproduction cycles globally.

NICE fertility guidelines (CG156, updated 2024) do not recommend ZIFT over standard IVF for any specific indication, as there is no evidence of superior live birth rates and the laparoscopic requirement adds procedural risk and cost.

ZIFT is not a first-line treatment for any standard infertility indication in contemporary reproductive medicine. Its historical use and current niche applications span the following scenarios:

• Unexplained infertility with failed IVF cycles: Historically, ZIFT was considered for couples with recurrent IVF failure where uterine implantation was suspected as a factor, under the hypothesis that tubal transfer might circumvent the implantation defect. This rationale is no longer well-supported by evidence.
• Male factor infertility: ZIFT was used alongside micromanipulation in the era before ICSI became widely available. Since ICSI (intracytoplasmic sperm injection) now addresses severe male factor infertility within standard IVF, this indication for ZIFT has largely disappeared.
• Uterine factor exclusion — primary contemporary indication: In women with an anatomically or functionally abnormal uterus where transcervical embryo transfer is not possible or is considered unlikely to succeed — for example, severe Asherman syndrome, uterine aplasia, or a history of multiple failed transfers despite good embryo quality — tubal transfer via ZIFT provides an alternative implantation pathway by delivering the zygote to the tube and allowing it to implant when it reaches a uterus via natural transport. This is the most defensible current indication.
• Cervical stenosis: When transcervical embryo transfer is impossible due to severe cervical stenosis that cannot be bypassed by ultrasound-guided techniques, laparoscopic ZIFT provides an alternative transfer route. Modern hysteroscopic methods and ultrafine transfer catheters have largely resolved most cervical access problems, making this indication uncommon.

ZIFT is not indicated for women without patent fallopian tubes, as the mechanism depends entirely on tubal transport of the transferred zygote to the uterine cavity.

Patient selection for ZIFT requires stringent criteria that reflect both the technical requirements of the procedure and the populations in which a benefit over standard IVF might be plausible:

• Patent fallopian tube(s): At least one healthy, anatomically normal, patent fallopian tube is an absolute prerequisite. Patency should be confirmed by hysterosalpingography (HSG) or laparoscopy with dye. Women with bilateral tubal occlusion, hydrosalpinges, or a history of bilateral salpingectomy are entirely ineligible for ZIFT.
• Sufficient ovarian reserve for stimulation: As with standard IVF, controlled ovarian hyperstimulation (COH) is required to retrieve multiple oocytes. Adequate antral follicle count and AMH are necessary for an adequate response.
• Fitness for laparoscopy and general anaesthesia: The ZIFT transfer step requires a formal laparoscopic procedure under general anaesthesia. Contraindications to laparoscopy (morbid obesity, severe adhesions, cardiorespiratory disease precluding pneumoperitoneum) are contraindications to ZIFT.
• Specific clinical indication justifying the added surgical risk: Given that standard IVF achieves equivalent or superior outcomes with less invasiveness, ZIFT should only be proposed when a clear, specific rationale exists — most often uterine factor, severe cervical inaccessibility, or a research protocol.
• Prior IVF failure with suspected implantation failure: Some centres still consider ZIFT for women with multiple unexplained IVF failures despite good embryo quality, under the hypothesis that a uterine receptivity problem might be bypassed via the tubal route. The evidence base for this application is limited.

Couples should receive detailed counselling comparing ZIFT and IVF success rates, costs, and procedural risks from a specialist reproductive medicine clinician before proceeding.

The ZIFT procedure follows IVF stimulation and fertilisation protocols, with the embryo transfer step replaced by laparoscopic tubal transfer:

• Step 1 — Controlled Ovarian Hyperstimulation (COH): Gonadotrophin injections (FSH with or without LH) are administered over 8–14 days, guided by serial transvaginal ultrasound and serum oestradiol monitoring. GnRH agonist or antagonist co-treatment prevents premature LH surge. Final oocyte maturation is triggered with hCG or GnRH agonist when follicles reach ≥18 mm.
• Step 2 — Transvaginal Oocyte Retrieval: Performed under transvaginal ultrasound guidance under sedation or general anaesthesia, 34–36 hours after trigger injection. Retrieved oocytes are identified in follicular fluid by the embryologist.
• Step 3 — Fertilisation: Oocytes are fertilised by standard insemination (sperm placed in culture medium with oocytes) or ICSI. Fertilisation is confirmed 16–18 hours after insemination by visualising two pronuclei (2PN) — the hallmark of successful fertilisation.
• Step 4 — Laparoscopic Tubal Transfer: Performed 24–48 hours after egg collection, when zygotes are confirmed to be at the 2PN stage. Under general anaesthesia, a laparoscope provides access to the fallopian tube. A transcervical or direct tubal cannula is used to deposit 1–2 zygotes into the fallopian tube approximately 3–5 cm from the uterotubal junction. Multiple zygotes may be cryopreserved for later use.
• Post-transfer luteal support: As in standard IVF, progesterone supplementation (pessaries, injection, or gel) is commenced from the day of egg collection and continued until the pregnancy test at 14 days, then to 10–12 weeks if pregnant.
• Cryopreservation of surplus zygotes and embryos: Surplus 2PN zygotes or cleavage-stage embryos not transferred can be cryopreserved by vitrification for future frozen embryo transfer (FET) cycles, avoiding repeat stimulation.

ZIFT offers specific theoretical and practical advantages over standard IVF in selected clinical situations:

• Confirmed fertilisation before surgical transfer: Unlike GIFT, which transfers gametes without knowledge of whether fertilisation will occur, ZIFT confirms fertilisation (2PN stage) before performing the laparoscopic transfer. This ensures that the surgical procedure is not performed in a cycle where fertilisation has failed entirely.
• Physiological early embryo environment: The fallopian tube provides growth factors, endocannabinoids, and a precisely regulated micro-environment that differs from in vitro culture media. For some embryos, tubal transport may better support early cleavage and zona pellucida interactions. Whether this translates into higher implantation rates over modern optimised culture conditions is unproven.
• Bypass of uterine transcervical transfer: In women where transcervical transfer is technically impossible (severe cervical stenosis, complex uterine anatomy) or repeatedly unsuccessful, laparoscopic ZIFT provides an alternative transfer route that avoids the uterine cavity entirely until the embryo arrives via natural tubal transport.
• Suitable for certain uterine factor cases: In women with endometrial inadequacy or structural uterine abnormalities limiting implantation, delivering the embryo via the tube allows it to reach the uterus at a later developmental stage under natural hormonal conditions, potentially improving implantation rates in these specific cases.
• Historical live birth rate data: In the 1990s, ZIFT was reported to have slightly higher per-cycle pregnancy rates than GIFT in some series due to the fertilisation confirmation step. Data from the Society for Assisted Reproductive Technology (SART) in the mid-1990s showed ZIFT live birth rates of 22–28% per cycle — comparable to IVF at that time.

ZIFT carries the same risks as standard IVF, plus the additional risks associated with laparoscopy and general anaesthesia for the transfer step:

IVF-shared risks:

• Ovarian hyperstimulation syndrome (OHSS): Exaggerated ovarian response to gonadotrophins; ranges from mild (abdominal bloating) to severe (massive ascites, haemoconcentration, renal impairment, thromboembolism). Risk is minimised by GnRH antagonist protocols and agonist trigger in high-responders.
• Multiple pregnancy: Transfer of more than one zygote risks twin or higher-order multiple pregnancy, with associated obstetric complications. Most guidelines recommend single zygote transfer to reduce this risk.
• Oocyte retrieval complications: Bleeding, infection, or injury to adjacent structures during transvaginal egg collection; rare but recognised.
• Ectopic pregnancy: ZIFT carries a theoretically higher risk of ectopic (tubal) pregnancy compared with standard IVF, as the zygote is placed in the tube rather than the uterus. Reported ectopic rates after ZIFT are 3–5%, somewhat higher than the 1–2% rate seen with standard IVF transcervical transfer.

ZIFT-specific (laparoscopy) risks:

• General anaesthesia: Standard risks of general anaesthesia including airway complications, aspiration, and adverse drug reactions.
• Laparoscopic injury: Bowel perforation, vascular injury during trocar insertion, haematoma formation — all rare (<0.5%) but recognised complications of laparoscopy.
• CO2 pneumoperitoneum: Shoulder pain from diaphragmatic irritation, gas embolism (very rare).
• Cycle cancellation: If fewer than expected zygotes develop after fertilisation, or if laparoscopy cannot be safely completed, the transfer step may be abandoned and embryos cryopreserved instead.

Post-ZIFT monitoring follows the standard IVF protocol, with recovery from the additional laparoscopic step also required:

• Recovery from laparoscopy: Most patients are discharged the same day or after a single night in hospital. Shoulder tip pain from residual CO2 gas is common and resolves within 24–48 hours. Port site soreness is managed with simple analgesia.
• Activity after laparoscopy: Light activities within 24–48 hours; return to office work within 2–5 days; avoid strenuous exercise and heavy lifting for 2 weeks.
• Luteal phase support: Progesterone supplementation begins on the day of egg collection and continues until the pregnancy test. If the test is positive, progesterone is maintained to 10–12 weeks of gestation to support the corpus luteum.
• Pregnancy test: A serum beta-hCG measurement is performed 14 days after the laparoscopic ZIFT transfer. A positive result is followed by serial hCG measurements every 48 hours to confirm doubling (indicating a viable intrauterine pregnancy).
• Early pregnancy ultrasound: A transvaginal ultrasound at 6–7 weeks confirms intrauterine location of the gestational sac and fetal cardiac activity. Given the modestly elevated ectopic risk with ZIFT, an early scan is particularly important to exclude tubal implantation.
• Frozen embryo transfer (FET) planning: If surplus zygotes or embryos were cryopreserved, a subsequent FET cycle can be planned after recovery from a failed or cancelled fresh cycle, avoiding repeat stimulation.
• Psychological support: As with all assisted reproduction, failed cycles should be followed by counselling to review the results, assess embryo quality, and plan the optimal next step — which may include repeat ZIFT, switching to blastocyst IVF transfer, or considering surrogacy if uterine implantation failure is suspected.

ZIFT is consistently more expensive than standard IVF due to the additional laparoscopic procedure, general anaesthesia, and longer operating theatre time required for the transfer step:

• United Kingdom: ZIFT is not routinely offered or funded by the NHS, as NICE does not recommend it over IVF. Private fertility clinics rarely offer it; where it is available, costs are typically 30–50% higher than standard IVF, placing cycles in the range of £4,500–£7,000, excluding medications.
• United States: ZIFT cycles (including stimulation, egg collection, fertilisation, laparoscopy, and transfer) typically cost USD 10,000–18,000 per cycle. Insurance coverage is unlikely to extend to ZIFT when it exceeds the cost of standard IVF without a specific clinical justification.
• India: IVF and ZIFT are available at significantly lower cost in accredited fertility centres. ZIFT cycles cost approximately INR 120,000–250,000 (USD 1,440–3,000) inclusive of stimulation medications and laparoscopy — representing savings of 70–80% compared with UK or US private pricing.
• Thailand and Malaysia: International fertility centres offer ZIFT for USD 3,000–6,000 per cycle, attracting medical tourists from Australia, the Middle East, and Europe.

Additional cost considerations:

• Ovarian stimulation medications (FSH injectables): USD 1,000–3,000 per cycle
• Embryology laboratory fees (fertilisation, culture, quality assessment)
• Cryopreservation and long-term storage of surplus zygotes
• Anaesthetist and laparoscopy theatre fees (separate billing at many centres)
• Monitoring scans and blood tests during stimulation

ZIFT has been largely displaced by improved IVF techniques and other assisted reproduction options. The following alternatives achieve equivalent or superior outcomes with less invasiveness in most clinical situations:

• Standard IVF with blastocyst transfer (Day 5): The dominant alternative and the de facto replacement for ZIFT in almost all clinical scenarios. Extended culture to the blastocyst stage (day 5–6) allows selection of the most developmentally competent embryos, improves synchrony with the endometrium, and achieves higher live birth rates per transfer than cleavage-stage or 2PN-stage transfer. Modern IVF culture systems provide optimised oxygen tension, growth factors, and amino acid supplementation that closely approximate the in vivo fallopian tube environment. NICE recommends single blastocyst transfer for most women under 37 to maximise live birth rates while minimising multiple pregnancy risk.
• GIFT (Gamete Intrafallopian Transfer): GIFT places both unfertilised eggs and prepared sperm directly into the fallopian tube via laparoscopy, allowing fertilisation to occur in the tube. GIFT was widely used before ICSI became available for male factor infertility and was acceptable in some religious traditions that prohibited in vitro fertilisation. Like ZIFT, it has largely been abandoned due to the inability to confirm fertilisation before surgery and the availability of equivalent IVF outcomes without laparoscopy. GIFT still has a role in specific religious contexts where in vitro fertilisation itself is not permissible but in vivo fertilisation via the tube is acceptable.
• IVF with ICSI: Intracytoplasmic sperm injection directly into the oocyte cytoplasm addresses male factor infertility, poor fertilisation rates, and previous fertilisation failure without the need for tubal transfer. ICSI within standard transcervical IVF is the first-line approach for most couples who historically would have been considered for ZIFT.
• Surrogacy (gestational carrier): For women with an absolute uterine factor — aplasia, irreparable Asherman syndrome, or absence of uterus — where tubal ZIFT cannot achieve implantation in the maternal uterus, a gestational carrier who gestates an embryo created from the couple's own gametes is the alternative, subject to legal frameworks in the relevant country.

The vast majority of couples previously considered for ZIFT are better served by optimised blastocyst IVF in a specialist centre with a high-quality embryology laboratory. ZIFT should only be proposed when a clearly documented clinical justification exists and after a detailed risk-benefit discussion comparing it with the leading alternative — blastocyst IVF.